<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39183848</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Integrative genomic analysis of the lung tissue microenvironment in SARS-CoV-2 and NL63 patients.</ArticleTitle><Pagination><StartPage>e32772</StartPage><MedlinePgn>e32772</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e32772</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e32772</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus has affected over 700 million people, and caused over 7 million deaths throughout the world as of April 2024, and continues to affect people through seasonal waves. While over 675 million people have recovered from this disease globally, the lingering effects of the disease are still under study. Long term effects of SARS-CoV-2 infection, known as 'long COVID,' include a wide range of symptoms including fatigue, chest pain, cellular damage, along with a strong innate immune response characterized by inflammatory cytokine production. Three years after the pandemic, data about long covid studies are finally emerging. More clinical studies and clinical trials are needed to understand and determine the factors that predispose individuals to these long-term side effects. In this methodology paper, our goal was to apply data driven approaches in order to explore the multidimensional landscape of infected lung tissue microenvironment to better understand complex interactions between viral infection, immune response and the lung microbiome of patients with (a) SARS-CoV-2 virus and (b) NL63 coronavirus. The samples were analyzed with several machine learning tools allowing simultaneous detection and quantification of viral RNA amount at genome and gene level; human gene expression and fractions of major types of immune cells, as well as metagenomic analysis of bacterial and viral abundance. To contrast and compare specific viral response to SARS-COV-2, we analyzed deep sequencing data from additional cohort of patients infected with NL63 strain of corona virus. Our correlation analysis of three types of RNA-seq based measurements in patients i.e. fraction of viral RNA (at genome and gene level), Human RNA (transcripts and gene level) and bacterial RNA (metagenomic analysis), showed significant correlation between viral load as well as level of specific viral gene expression with the fractions of immune cells present in lung lavage as well as with abundance of major fractions of lung microbiome in COVID-19 patients. Our methodology-based proof-of-concept study has provided novel insights into complex regulatory signaling interactions and correlative patterns between the viral infection, inhibition of innate and adaptive immune response as well as microbiome landscape of the lung tissue. These initial findings could provide better understanding of the diverse dynamics of immune response and the side effects of the SARS-CoV-2 infection and demonstrates the possibilities of the various types of analyses that could be performed from this type of data.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhuvaneshwar</LastName><ForeName>Krithika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Georgetown-Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center, Washington DC, 20007, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhavan</LastName><ForeName>Subha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Georgetown-Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center, Washington DC, 20007, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gusev</LastName><ForeName>Yuriy</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Georgetown-Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center, Washington DC, 20007, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">Genomics</Keyword><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Metagenomics</Keyword><Keyword MajorTopicYN="N">Microbiome</Keyword><Keyword MajorTopicYN="N">RNA-Seq</Keyword><Keyword MajorTopicYN="N">SARS-COV-2</Keyword><Keyword MajorTopicYN="N">Viroinformatics</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39183848</ArticleId><ArticleId IdType="pmc">PMC11341340</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e32772</ArticleId><ArticleId IdType="pii">S2405-8440(24)08803-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Coronavirus Pandemic  Secondary COVID-19 coronavirus pandemic. 2021. https://www.worldometers.info/coronavirus/</Citation></Reference><Reference><Citation>Al-Jahdhami I., Al-Naamani K., Al-Mawali A. The post-acute COVID-19 syndrome (long COVID) Oman Med. J. 2021;36(1):e220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838343</ArticleId><ArticleId IdType="pubmed">33537155</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 rapid resource center &gt; age distribution and critical illness severity of COVID-19 secondary COVID-19 rapid resource center &gt; age distribution and critical illness severity of COVID-19 2021. https://www.sccm.org/COVID19RapidResources/Resources/Age-Distribution-and-Critical-Illness-Severity-of</Citation></Reference><Reference><Citation>Ma Q., Liu J., Liu Q., et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw. Open. 2021;4(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Global research on coronavirus disease (COVID-19). Secondary Global research on coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov. Last Accessed April 24 2024.</Citation></Reference><Reference><Citation>Communications N. Top 25 COVID-19 articles of 2022. Secondary top 25 COVID-19 articles of 2022. 2023. https://www.nature.com/collections/ahdejdadbd</Citation></Reference><Reference><Citation>Communications N. The top 25 COVID-19 articles of 2023. Secondary the top 25 COVID-19 articles of 2023. 2024. https://www.nature.com/collections/gjajjhfcha</Citation></Reference><Reference><Citation>Nature S. Coronavirus Collections.</Citation></Reference><Reference><Citation>PMC. PMC COVID-19 Collection  Secondary PMC COVID-19 collection. https://www.ncbi.nlm.nih.gov/pmc/about/covid-19/</Citation></Reference><Reference><Citation>Khanna V.V., Chadaga K., Sampathila N., et al. A machine learning and explainable artificial intelligence triage-prediction system for COVID-19. Decision Analytics Journal. 2023;7(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10746430</ArticleId><ArticleId IdType="pubmed">38144333</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadaga K., Prabhu S., Bhat V., et al. An explainable multi-class decision support framework to predict COVID-19 prognosis utilizing biomarkers. Cogent Engineering. 2023;10(2)</Citation></Reference><Reference><Citation>Chadaga K., Prabhu S., Bhat V., et al. Artificial intelligence for diagnosis of mild-moderate COVID-19 using haematological markers. Ann. Med. 2023;55(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10339777</ArticleId><ArticleId IdType="pubmed">37436038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O., Merino E., Leon-Ramirez J.M., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J. Infect. 2021;82(3):378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Candan S.A., Elibol N., Abdullahi A. Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19. Physiother. Theory Pract. 2020;36(6):663&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">32419564</ArticleId></ArticleIdList></Reference><Reference><Citation>Predicting &#x2018;long COVID syndrome&#x2019; with help of a smartphone app. Secondary predicting &#x2018;long COVID syndrome&#x2019; with help of a smartphone app. https://directorsblog.nih.gov/tag/post-acute-sequelae-of-covid-19/</Citation></Reference><Reference><Citation>US health agency will invest $1 billion to investigate &#x2018;long COVID&#x2019;. Secondary US health agency will invest $1 billion to investigate &#x2018;long COVID&#x2019; 2021. https://www.nature.com/articles/d41586-021-00586-y</Citation></Reference><Reference><Citation>&#xa3;18.5 million awarded to new research projects to understand and treat long COVID. Secondary &#xa3;18.5 million awarded to new research projects to understand and treat long COVID 2021. https://www.nihr.ac.uk/news/185-million-awarded-to-new-research-projects-to-understand-and-treat-long-covid/26895. Last Accessed March 30, 2021.</Citation></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., et al. Author Correction: long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21(6):408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10408714</ArticleId><ArticleId IdType="pubmed">37069455</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann A.J., Vogel J. Cross-species RNA-seq for deciphering host-microbe interactions. Nat. Rev. Genet. 2021;22(6):361&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">33597744</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann A.J., Gorski S.A., Vogel J. Dual RNA-seq of pathogen and host. Nat. Rev. Microbiol. 2012;10(9):618&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">22890146</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Rasool S., Fielding B.C. Understanding human coronavirus HCoV-NL63. Open Virol. J. 2010;4:76&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918871</ArticleId><ArticleId IdType="pubmed">20700397</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards K.A., Glover M., Crawford J.C., et al. Circulating CD4 T cells elicited by endemic coronaviruses display vast disparities in abundance and functional potential linked to antigen specificity and age. J. Infect. Dis. 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928818</ArticleId><ArticleId IdType="pubmed">33556959</ArticleId></ArticleIdList></Reference><Reference><Citation>NCBI SRA SRP249613  Secondary NCBI SRA SRP249613. https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP249613</Citation></Reference><Reference><Citation>Zhou P., Yang X.L., Wang X.G., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Respiratory Sample from Hospitalized Children with SARI (PRJA601331).</Citation></Reference><Reference><Citation>Zhang L., Gan M., Zhang Z., et al. Complete genome sequences of five human coronavirus NL63 strains causing respiratory illness in hospitalized children in China. Microbiol Resour Announc. 2020;9(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7033275</ArticleId><ArticleId IdType="pubmed">32079638</ArticleId></ArticleIdList></Reference><Reference><Citation>NCBI Virus. Secondary NCBI Virus. https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&amp;CollectionDate_dr=1950-01-01T00:00:00Z%20TO%20NOW&amp;CreateDate_dt=1950-01-01T00:00:00Z%20TO%20NOW&amp;HostLineagess=Homo%20sapiens%20(human),%20taxid:9606&amp;SourceDBs=RefSeq&amp;Completenesss=complete. Last Accessed April 5, 2021.</Citation></Reference><Reference><Citation>Bhuvaneshwar K., Song L., Madhavan S., et al. viGEN: an open source pipeline for the detection and quantification of viral RNA in human tumors. Front. Microbiol. 2018;9:1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5996193</ArticleId><ArticleId IdType="pubmed">29922260</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9(4):357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Song L., Breitwieser F.P., et al. Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res. 2016;26(12):1721&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131823</ArticleId><ArticleId IdType="pubmed">27852649</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Dewey C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinf. 2011;12:323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Correction: the cancer genomics Cloud: collaborative, reproducible, and democratized-A new paradigm in large-scale computational research. Cancer Res. 2018;78(17):5179.</Citation><ArticleIdList><ArticleId IdType="pubmed">30181303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J.W., Lehnert E., Sethi A., et al. The cancer genomics Cloud: collaborative, reproducible, and democratized-A new paradigm in large-scale computational research. Cancer Res. 2017;77(21):e3&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832960</ArticleId><ArticleId IdType="pubmed">29092927</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B., Khodadoust M.S., Liu C.L., et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 2018;1711:243&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5895181</ArticleId><ArticleId IdType="pubmed">29344893</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman A.M., Liu C.L., Green M.R., et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods. 2015;12(5):453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Centrifuge Classifier for metagenomic sequences  Secondary Centrifuge classifier for metagenomic sequences. https://ccb.jhu.edu/software/centrifuge/</Citation></Reference><Reference><Citation>Breitwieser F.P., Salzberg S.L. Pavian: interactive analysis of metagenomics data for microbiome studies and pathogen identification. Bioinformatics. 2020;36(4):1303&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8215911</ArticleId><ArticleId IdType="pubmed">31553437</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavian Secondary pavian. https://github.com/fbreitwieser/pavian</Citation></Reference><Reference><Citation>R Core Team  . R: A language and environment for statistical computing; 2017. R: A Language and Environment for Statistical Computing.https://www.R-project.org/ Secondary R Core Team (2017)</Citation></Reference><Reference><Citation>Severe acute respiratory syndrome (SARS)  Secondary Severe acute respiratory syndrome (SARS) https://www.cdc.gov/sars/index.html</Citation></Reference><Reference><Citation>Subramanyam V., Paramshivan D., Kumar A., et al. Using Sankey diagrams to map energy flow from primary fuel to end use. Energy Convers. Manag. 2015;91:342&#x2013;352.</Citation></Reference><Reference><Citation>Macrophages  Secondary macrophages. https://www.immunology.org/public-information/bitesized-immunology/cells/macrophages</Citation></Reference><Reference><Citation>Wikipedia. Macrophages. Secondary Macrophages. https://en.wikipedia.org/wiki/Macrophage. Last Accessed April 19, 2021.</Citation></Reference><Reference><Citation>Meidaninikjeh S., Sabouni N., Marzouni H.Z., et al. Monocytes and macrophages in COVID-19: friends and foes. Life Sci. 2021;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834345</ArticleId><ArticleId IdType="pubmed">33454368</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P., Li W., Xie J., et al. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta. 2020;509:280&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv J., Wang Z., Qu Y., et al. Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages. Cell Discov. 2021;7(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043100</ArticleId><ArticleId IdType="pubmed">33850112</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wu H., Yao X., et al. Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell. Mol. Immunol. 2021;5:1305&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976727</ArticleId><ArticleId IdType="pubmed">33742186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikipedia. Natural Killer Cell  Secondary natural killer cell. https://en.wikipedia.org/wiki/Natural_killer_cell</Citation></Reference><Reference><Citation>Zafarani A., Razizadeh M.H., Pashangzadeh S., et al. Natural killer cells in COVID-19: from infection, to vaccination and therapy. Future Virol. 2023 doi: 10.2217/fvl-2022-0040.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2022-0040</ArticleId><ArticleId IdType="pmc">PMC10013930</ArticleId><ArticleId IdType="pubmed">36936055</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett A. The potential effect of novel coronavirus SARS-CoV-2 on NK cells; A perspective on potential therapeutic interventions. Front. Immunol. 2020;11:1692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365845</ArticleId><ArticleId IdType="pubmed">32754162</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Project for SARS BG The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. Am. J. Clin. Pathol. 2004;121(4):507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110090</ArticleId><ArticleId IdType="pubmed">15080302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao C., Tao X., Cui W., et al. Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients. Exp. Hematol. Oncol. 2021;10(1):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839286</ArticleId><ArticleId IdType="pubmed">33504359</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov  NCT04634370: fase I clinical trial on NK cells for COVID-19. Secondary NCT04634370: fase I clinical trial on NK cells for COVID-19. https://clinicaltrials.gov/ct2/show/NCT04634370</Citation></Reference><Reference><Citation>Boosting natural killer cells for the treatment of COVID-19. Secondary boosting natural killer cells for the treatment of COVID-19 2021. https://pediatricsnationwide.org/https://pediatricsnationwide.org/2021/01/05/boosting-natural-killer-cells-for-the-treatment-of-covid-19/</Citation></Reference><Reference><Citation>Berentschot J.C., Drexhage H.A., Aynekulu Mersha D.G., et al. Immunological profiling in long COVID: overall low grade inflammation and T-lymphocyte senescence and increased monocyte activation correlating with increasing fatigue severity. Front. Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10597688</ArticleId><ArticleId IdType="pubmed">37881427</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam R.F., Hossain M.M., Ibne Momen A.B., et al. COVID-19 with multiple bacterial Co-infections: a case report. European Journal of Medical and Health Sciences. 2021;3(1):1&#x2013;4.</Citation></Reference><Reference><Citation>Mahmoudi H. Bacterial co-infections and antibiotic resistance in patients with COVID-19. GMS Hyg Infect Control. 2020;15:Doc35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747008</ArticleId><ArticleId IdType="pubmed">33391970</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford B.J., So M., Raybardhan S., et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin. Microbiol. Infect. 2020;26(12):1622&#x2013;1629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832079</ArticleId><ArticleId IdType="pubmed">32711058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason C.Y., Kanitkar T., Richardson C.J., et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J. Antimicrob. Chemother. 2021;(5):1323&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928909</ArticleId><ArticleId IdType="pubmed">33463683</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T., Wu J., Zeng Y., et al. SARS-CoV-2 triggered oxidative stress and abnormal energy metabolism in gut microbiota. MedComm. 2020;3(1):e112. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906553</ArticleId><ArticleId IdType="pubmed">35281785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty A., Diwan A. NL63: a better surrogate virus for studying SARS-CoV-2. Integrative Molecular Medicine. 2020;8(2)</Citation></Reference><Reference><Citation>Castillo G., Nelli R.K., Phadke K.S., et al. SARS-CoV-2 is more efficient than HCoV-NL63 in infecting a small subpopulation of ACE2+ human respiratory epithelial cells. Viruses. 2023;15(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10059808</ArticleId><ArticleId IdType="pubmed">36992445</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards K.A., Glover M., Crawford J.C., et al. Circulating CD4 T cells elicited by endemic coronaviruses display vast disparities in abundance and functional potential linked to both antigen specificity and age. J. Infect. Dis. 2021;(9):1555&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928818</ArticleId><ArticleId IdType="pubmed">33556959</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H.X., Lee W.S., Wragg K.M., et al. Adaptive immunity to human coronaviruses is widespread but low in magnitude. Clin Transl Immunology. 2021;10(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7968850</ArticleId><ArticleId IdType="pubmed">33747512</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarjour N.N., Masopust D., Jameson S.C. T cell memory: understanding COVID-19. Immunity. 2021;54(1):14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749639</ArticleId><ArticleId IdType="pubmed">33406391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilich T., Nelde A., Heitmann J.S., et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci. Transl. Med. 2021;590</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128286</ArticleId><ArticleId IdType="pubmed">33723016</ArticleId></ArticleIdList></Reference><Reference><Citation>UKRI  The immune system and long COVID. Secondary the immune system and long COVID March 1, 2021 2021. https://www.ukri.org/our-work/tackling-the-impact-of-covid-19/understanding-coronavirus-covid-19-and-epidemics/the-immune-system-and-long-covid/</Citation></Reference><Reference><Citation>T cells found in COVID-19 patients &#x2018;bode well&#x2019; for long-term immunity. Secondary T cells found in COVID-19 patients &#x2018;bode well&#x2019; for long-term immunity. 2020. https://www.sciencemag.org/news/2020/05/t-cells-found-covid-19-patients-bode-well-long-term-immunity May. 14, 2020.</Citation></Reference><Reference><Citation>Alajez H.S.N.M. Identification of PBMC-based molecular signature associational with COVID-19 disease severity. Heliyon. 2021;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057768</ArticleId><ArticleId IdType="pubmed">33898797</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves Machine Learning Tool for COVID-19 Screening  Secondary FDA approves machine learning tool for COVID-19 screening march 23, 2021. 2021. https://healthitanalytics.com/news/fda-approves-machine-learning-tool-for-covid-19-screening</Citation></Reference><Reference><Citation>Zoabi Y., Deri-Rozov S., Shomron N. Machine learning-based prediction of COVID-19 diagnosis based on symptoms. NPJ Digit Med. 2021;4(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7782717</ArticleId><ArticleId IdType="pubmed">33398013</ArticleId></ArticleIdList></Reference><Reference><Citation>AI  Machine learning tools help predict COVID-19 outcomes. Secondary AI, machine learning tools help predict COVID-19 outcomes dec 21. 2020 2020. https://healthitanalytics.com/news/ai-machine-learning-tools-help-predict-covid-19-outcomes</Citation></Reference><Reference><Citation>Lyons Y.A., Wu S.Y., Overwijk W.W., et al. Immune cell profiling in cancer: molecular approaches to cell-specific identification. npj Precis. Oncol. 2017;1(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5871917</ArticleId><ArticleId IdType="pubmed">29872708</ArticleId></ArticleIdList></Reference><Reference><Citation>Testing a new COVID-19 test: how T-cells beat antibodies in helping to detect past infections. Secondary Testing a new COVID-19 test: How T-cells beat antibodies in helping to detect past infections February 26. 2021 https://www.geekwire.com/2021/testing-new-covid-19-test-t-cells-beat-antibodies-detecting-past-infections/</Citation></Reference><Reference><Citation>NPR  New clues to the biology of long COVID are starting to emerge. Secondary New clues to the biology of long COVID are starting to emerge 2021. https://www.npr.org/sections/health-shots/2021/11/12/1053509795/long-covid-causes-treatment-clues</Citation></Reference><Reference><Citation>Haran J.P., Bradley E., Zeamer A.L., et al. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021;6(20)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564890</ArticleId><ArticleId IdType="pubmed">34403368</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J., et al. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature. 2021;590(7844):29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoantibody Wikipedia. Secondary autoantibody. https://en.wikipedia.org/wiki/Autoantibody</Citation></Reference><Reference><Citation>Liu J., Yang X., Wang H., et al., The analysis of the long-term impact of SARS-CoV-2 on the cellular immune system in individuals recovering from COVID-19 reveals a profound NKT cell impairment, mBio. 2021 Apr 27;12(2):e00085-21. doi: 10.1128/mBio.00085-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092197</ArticleId><ArticleId IdType="pubmed">33906918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L., Mescia F., Turner L., et al. Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19. medRxiv. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses across a clinically diverse cohort of individuals recovering from COVID-19. 2021. medRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>